It is demonstrated that chEpmA serves as a versatile dual-specificity platform: it efficiently charges tRNAs with the non-canonical backbone (R)-β-lysine, and a single substitution unlocks the scaffold for α-substrates, thereby enabling a broad spectrum of post-translational modifications previously inaccessible to genetic code expansion.
Abstract
The ribosome’s DNA-encoded production of defined polymer sequences is naturally limited to 22 amino acids. Although the translation machinery has the latent capacity to polymerize backbone-modified substrates, including β-amino acids, this potential is constrained by the intrinsic α-selectivity of native aminoacyl-tRNA synthetases. Here, we address this limitation by “reverse engineering” the Escherichia coli protein ligase EpmA. Naturally activating (R)-β-lysine, EpmA evolved to discard its tRNA-binding domain in favor of protein recognition. By grafting the anticodon-binding domain of the canonical lysyl-tRNA synthetase, LysRS, onto EpmA, we created the chimeric enzyme chEpmA. To our knowledge, this represents the first successful reprogramming of a protein ligase into a functional aminoacyl-tRNA synthetase. We demonstrate that chEpmA serves as a versatile dual-specificity platform: it efficiently charges tRNAs with the non-canonical backbone (R)-β-lysine, and a single substitution unlocks the scaffold for α-substrates, thereby enabling a broad spectrum of post-translational modifications previously inaccessible to genetic code expansion. This repertoire ranges from acylated lysines such as Nε-succinyl-(S)-α lysine (Ksucc) and bulky modifications such as biocytin to advanced glycation end products (AGEs) including Nε-carboxymethyl-(S)-α lysine (CML). Our work establishes a structural blueprint for mobilizing non-canonical substrates, paving the way for the biosynthesis of protease-resistant peptidomimetics and next-generation therapeutics.
Genetic code expansion enables the site-specific installation of noncanonical amino acids (ncAAs) into proteins, but its limited efficiency in eukaryotes remains a major barrier to broader application. Here we establish a visual, plug-and-play screening platform to evolve 18S ribosomal DNA in Saccharomyces cerevisiae a...
Xiao-Xu Chen, Wentao Shen, Xian-Qing Chen et al.· Synthetic and Systems Biotec...· 0 citations
The strategy of integrating metagenomic bioprospecting with cell-free screening and cell-based engineering will accelerate the discovery and optimization of orthogonal translation systems for genetic code expansion.
Kosuke Seki, Michael T. A. Nguyen, Petar I. Penev et al.· ACS Synthetic Biology· 0 citations
These findings establish the mechanistic feasibility of a ribosome translating its own rRNA in vivo and in vitro, offering a versatile platform for orthogonal protein production and insights into the origin of translation.
Kasra Alizadeh, D. Klepacki, N. Vázquez-Laslop et al.· Nature· 0 citations
A ribozyme that can charge a tRNA with amino acids and discriminate between cognate and non-cognate tRNAs is of interest because an RNA with this ability may have been a critical for translation in the transition from the RNA world. In addition, it could provide a tool for incorporating non-canonical amino acids for bi...
R. Gan, Ji Chen, Gerald Manuel et al.· bioRxiv· 0 citations
The potential of BpyAla-mediated nucleic acid cleavage is discussed, with emphasis on the development of next-generation BpyAla analogues, the exploration of alternative metal cofactors, cooperative and multi-residue design strategies, and the expansion of compatible protein scaffolds and nucleic acid substrates.
Eryn Lundrigan, Matthew T. O'Neill, J. P. Pezacki· Frontiers in Chemical Biolog...· 0 citations
The standard genetic code uses 64 codons to encode 20 canonical amino acids across domains of life. New-to-nature genetic codes enable new chemistries, therapeutics and ecosystem engineering, but recoding the genome of an organism is exceptionally challenging1, 2, 3, 4, 5–6. Here we describe automated genetic tRNA expa...
Felix Radford, Nayan Sapers, Hana M. Burgess et al.· Nature· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.